Loading…
Protalix BioTherapeutics, Inc. is projected to rise to $3.26 by 2027, a +39% move from its current price of $2.35. PLX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.30 | $2.35 | $2.40 | +0.10% |
| Jul 14 | $2.28 | $2.35 | $2.42 | +0.20% |
| Jul 15 | $2.27 | $2.35 | $2.44 | +0.31% |
| Jul 16 | $2.26 | $2.35 | $2.46 | +0.41% |
| Jul 17 | $2.25 | $2.36 | $2.47 | +0.51% |
| Jul 18 | $2.24 | $2.36 | $2.48 | +0.61% |
| Jul 19 | $2.23 | $2.36 | $2.50 | +0.72% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.23 | $2.36 | $2.50 | +0.72% |
| Week 2 | $2.20 | $2.38 | $2.57 | +1.44% |
| Week 3 | $2.18 | $2.40 | $2.64 | +2.16% |
| Week 4 | $2.16 | $2.41 | $2.70 | +2.89% |
| Week 5 | $2.15 | $2.43 | $2.75 | +3.63% |
| Week 6 | $2.14 | $2.45 | $2.80 | +4.37% |
| Week 7 | $2.13 | $2.47 | $2.85 | +5.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company markets Elelyso for the treatment of Gaucher disease and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
PLX trades at $2.35 per share and has a market cap of $189.34M. It is ranked 3674 by market capitalization. The current price sits in a landscape of forecasted upside, with a long-run path thatprojects higher averages and sizable ROI across multiple years, including a 2030 average price of $4.23 and a 2050 average price of $26.35.
These forecasts imply meaningful upside from the current level.
A major floor 23.2% below — a decisive break under it would weaken the trend.
The nearest floor, 16.4% below — buyers have tended to step in here.
The nearest ceiling, 4.1% above — a clean break opens room to run.
A major ceiling 23.7% above — clearing it would confirm fresh momentum.
Key PLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.37 | Sell | $2.38 | Sell |
| MA 10 | $2.34 | Buy | $2.33 | Buy |
| MA 20 | $2.24 | Buy | $2.26 | Buy |
| MA 50 | $2.11 | Buy | $2.20 | Buy |
| MA 100 | $2.30 | Buy | $2.20 | Buy |
| MA 200 | $2.21 | Buy | $2.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.55 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 124.96 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 12.44 | Buy |
| Bollinger %B (20,2) | 0.91 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.49 | Buy |
| Awesome (5,34) | 0.22 | Buy |
| Ultimate (7,14,28) | 71.43 | Sell |
| Momentum (10) | 0.22 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 2.41 | Sell |
| ADX (14) | 23.27 | Buy |
| ATR (14) | 0.04 | Info |
The near-term technical picture is bullish. The RSI14 is 70, indicating bullish momentum, with the 30-day sentiment described as BULLISH.
Near-term price structure shows a SMA50 of $2.08 and a SMA200 of $2.19. Key support is at $1.90 and resistance at $2.35. The 30-day price range spans from $2.00 to $2.77, outlining the immediate trading corridor for PLX.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.74 | $2.35 | $3.34 | 0% | Neutral | |
| $2.65 | $3.26 | $4.21 | +39% | Bullish | |
| $2.83 | $3.55 | $4.71 | +51% | Bullish | |
| $3.27 | $4.18 | $5.68 | +78% | Bullish | |
| $3.48 | $4.52 | $6.26 | +93% | Bullish | |
| $3.76 | $4.95 | $6.97 | +111% | Bullish | |
| $4.93 | $6.56 | $9.39 | +180% | Bullish | |
| $5.44 | $7.32 | $10.63 | +212% | Bullish | |
| $5.71 | $7.77 | $11.43 | +231% | Bullish | |
| $6.18 | $8.51 | $12.67 | +263% | Bullish | |
| $9.61 | $13.88 | $21.73 | +492% | Bullish | |
| $19.51 | $30.53 | $51.52 | +12.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.74 | $2.35 | $2.82 | +0.00% |
| August 2026 | $2.13 | $2.50 | $3.00 | +6.69% |
| September 2026 | $2.18 | $2.57 | $3.11 | +2.86% |
| October 2026 | $2.17 | $2.57 | $3.14 | -0.01% |
| November 2026 | $2.21 | $2.63 | $3.22 | +2.09% |
| December 2026 | $2.27 | $2.71 | $3.34 | +3.11% |
Click any year to see its month-by-month PLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PLX price prediction for 2026 points to an average of $2.35 (low $1.74, high $3.34) — a potential gain of 0% on today's $2.35. A consolidation phase looks the most probable path here.
In 2027, PLX is projected to trade between $2.65 and $4.21, averaging $3.26 — a potential gain of +39% from today's $2.35. That is up +39% on the projected 2026 average. Momentum favours further upside here.
Protalix BioTherapeutics, Inc.'s 2028 outlook centres on $3.55, within a $2.83 to $4.71 range. That is up +9% on the projected 2027 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, PLX could reach as high as $5.68, with a base case around $4.18 and support toward $3.27 — roughly +78% from $2.35. Momentum favours further upside here.
Expect PLX to range from $3.48 to $6.26 through 2030. The $4.52 average target implies a +93% move from current prices. That is up +8% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PLX price prediction for 2031 points to an average of $4.95 (low $3.76, high $6.97) — a potential gain of +111% on today's $2.35. Momentum favours further upside here.
In 2032, PLX is projected to trade between $4.93 and $9.39, averaging $6.56 — a potential gain of +180% from today's $2.35. That is up +33% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Protalix BioTherapeutics, Inc.'s 2033 outlook centres on $7.32, within a $5.44 to $10.63 range. That is up +12% on the projected 2032 average. That marks a +212% change versus current levels. Momentum favours further upside here.
By 2034, PLX could reach as high as $11.43, with a base case around $7.77 and support toward $5.71 — roughly +231% from $2.35. Buyers look set to stay in control over this stretch.
Expect PLX to range from $6.18 to $12.67 through 2035. The $8.51 average target implies a +263% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The PLX price prediction for 2040 points to an average of $13.88 (low $9.61, high $21.73) — a potential gain of +492% on today's $2.35. Buyers look set to stay in control over this stretch.
In 2050, PLX is projected to trade between $19.51 and $51.52, averaging $30.53 — a potential gain of +12.0x from today's $2.35. That is up +120% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PLX today (≈ 426.439232 PLX) could be worth
$13,018.84
+$12,018.84 (+1202%) by 2050 · US Dollar
Based on the average projected PLX price of $30.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PLXwould be worth at today's price.
$1,000 invested in PLX on Jul 10, 2025 (≈ 675.675667 PLX) would be worth
$1,584.46
+$584.46 (+58.4%) today · 1.58× · US Dollar
Based on a PLX entry price of $1.48 vs. today's $2.35.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.32 | $1,010.78 | +1.1% |
| 1 month ago | $1.97 | $1,190.36 | +19.0% |
| 3 months ago | $2.3 | $1,019.57 | +2.0% |
| 6 months ago | $2.1 | $1,116.67 | +11.7% |
| 1 year ago | $1.48 | $1,584.46 | +58.4% |
| All time (5.0y) ago | $1.68 | $1,395.83 | +39.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PLX forecast.
Our base-case forecast reaches $4.70 around 2031.
Implied market cap at $4.70: $378.69M
The multi-year forecast shows a clear path of higher prices through 2035 and beyond, with rising average prices and corresponding ROI. For 2026, the min is $1.74, the avg is $2.35, and the max is $3.40 with a neutral sentiment.
From 2027 to 2035, the outlook strengthens: 2027 avg $3.23, min $2.59, max $4.25, ROI 37.4, sentiment BULLISH; 2028 avg $3.51, min $2.75, max $4.78, ROI 49.4, sentiment BULLISH; 2029 avg $4.03, min $3.09, max $5.62, ROI 71.3, sentiment BULLISH; 2030 avg $4.23, min $3.18, max $6.04, ROI 80, sentiment BULLISH; 2031 avg $4.63, min $3.42, max $6.74, ROI 96.8, sentiment BULLISH; 2032 avg $6.15, min $4.49, max $9.12, ROI 161.9, sentiment BULLISH; 2033 avg $6.79, min $4.88, max $10.23, ROI 189, sentiment BULLISH; 2034 avg $7.17, min $5.08, max $10.96, ROI 205.1, sentiment BULLISH; 2035 avg $7.73, min $5.41, max $11.97, ROI 228.9, sentiment BULLISH.
The forecast rises markedly by 2040: avg $12.49, min $8.24, max $20.49, ROI 431.3, sentiment BULLISH. By 2050 the trajectory extends to an avg of $26.35, min $15.72, max $47.04, ROI 1021.4, sentiment BULLISH. These figures point to a long-run upside with substantial potential gains, tempered by the usual uncertainties of biotechnology development and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $4.23 with a min of $3.18 and a max of $6.04, and an ROI of 80, with bullish sentiment.
Across the forecast, sentiment turns bullish from 2027 onward, with higher average prices and ROI over time (e.g., 2030 at 4.23 with ROI 80 and 2040 at 12.49 with ROI 431.3; 2050 at 26.35 with ROI 1021.4). The 2026 view is neutral, indicating mixed near-term prospects.
Yes. The 2033 forecast lists a max of $10.23, which exceeds $10.
For 2040 the avg price is $12.49, with a min of $8.24 and a max of $20.49, and ROI of 431.3, with bullish sentiment.
Current price is $2.35 and market cap is $189.34M, with a rank of 3674.
Protalix BioTherapeutics, Inc. Community Discussion
0Share your Protalix BioTherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.